New drug tested to make Cancer-Killing CAR-T therapy last longer
NCT ID NCT05801939
Summary
This study is for people with multiple myeloma that has come back or stopped responding to treatment. It tests if adding a new drug called cevostamab, given as an IV infusion every 3 weeks, after a standard CAR-T cell therapy can help keep the cancer in remission. The main goal is to see if this combination helps more patients achieve a deep, undetectable level of remission one year after their CAR-T treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.